RxDoctor Payments Data

Lubna Chaudhary, MD

Hematology & Oncology · Milwaukee, WINPI 1912136763

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $31,668 of the $33,846 with a category attached, or 93.6%. 8 manufacturers reported payments, led by Novartis at 36.4% of the total. Among hematology & oncology clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$33,846in general payments, 2019–2025

Across 32 payments — averaging $1057.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$12K
  • AstraZeneca$9K
  • Gilead$8K
  • Daiichi Sankyo Inc.$2K
  • Seagen Inc.$1K
  • Puma Biotechnology, Inc.$1K
  • plus $356 from 2 others
$185,697in research payments, 2019–2025

Across 19 payments — averaging $9773.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$116K
  • Genentech, Inc.$69K
  • Stemline Therapeutics Inc.$145

What the payments were for

  • Consulting fees$31,66894%
  • Grants$3501%
  • Travel & lodging$9043%
  • Food & beverage$9243%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis11$12,324
AstraZeneca8$9,361
Gilead6$7,740
Daiichi Sankyo Inc.2$1,640
Seagen Inc.1$1,375
Puma Biotechnology, Inc.2$1,050
Genentech, Inc.1$340
Lilly USA, LLC1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,846 in reported general payments places this provider in the 90th percentile of 248 hematology & oncology providers in Wisconsin.

See all hematology & oncology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$35,814
Medicare patients
171
Services billed
505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib18$276,223
Anastrozole294$5,308
Exemestane21$3,031
Tamoxifen Citrate94$2,299
Letrozole30$885
Ondansetron Hcl36$521
Dexamethasone24$328
Lidocaine-PrilocaineLidocaine/Prilocaine14$155
Olanzapine21$134
Alendronate Sodium11$75

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$16$13421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 248 hematology & oncology providers in Wisconsin.

Other hematology & oncology in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →